Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
402 results about "Native protein" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Native protein. The protein inside the cell that is in its native or natural state and unaltered by denaturing agent, such as heat, chemical, enzyme action, or the exigencies of extraction. A native protein is in its functional form, particularly in a simple, unbranched chain of amino acids while assuming a specific 3D shape.
Expression of heterologous proteins
An expression system which provides heterologous proteins expressed by a non-native host organism but which have native-protein-like biological activity and / or structure. Disclosed are vectors, expression hosts and methods for expressing the heterologous proteins. The expression system involves co-expression of protein factor(s) which is / are capable of catalyzing disulphide bond formation and desired heterologous protein(s). The expression system is presented using yeast cells as the preferred host, protein disulphide isomerase (PDI) and thioredoxin (TRX) as the preferred examples of the protein factors and HCV-E2715 envelope glycoprotein and human FIGF as the preferred examples of the heterologous proteins.
Owner:NOVARTIS AG
Ultrasensitive sensor and rapid detection of analytes
The present invention relates to systems and methods for real time, rapid detection, identification, and enumeration of a wide variety of analytes, which include but are not limited to, cells (Eukarya, Eubacteria, Archaea), microorganisms, organelles, viruses, proteins (recombinant or natural proteins), nucleic acids, prionss, and any chemical, metabolites, or biological markers. The systems and methods, which include the laser / optic / electronic units, the analytic software, the assay methods and reagents, and the high throughput automation, are particularly adapted to detection, identification, and enumeration of pathogens and non-pathogens in contaminated foods, clinical samples, and environmental samples. Other microorganisms that can be detected with the present invention include clinical pathogens, protozoa and, viruses.
Owner:KIM LAB INC
Matrix composed of a naturally-occurring protein backbone cross linked by a synthetic polymer and methods of generating and using same
The present invention relates to biodegradable scaffolds composed of a naturally-occurring protein backbone cross-linked by a synthetic polymer. Specifically, the present invention provides PEGylated-fibrinogen scaffold and methods of generating and using same for treating disorders requiring tissue regeneration.
Owner:REGENTIS BIOMATERIALS
Prolonged release bioadhesive therapeutic systems
The present invention concerns a prolonged release bioadhesive mucosal therapeutic system containing at least one active principle, with an active dissolution test of more than 70% over 8 hours and to a method for its preparation. The bioadhesive therapeutic system may be in tablet form and may contain quantities of natural proteins representing at least 50% by weight of active principle and at least 20% by weight of the tablet, between 10% and 20% of a hydrophilic polymer, and compression excipients, and may contain between 4% and 10% of an alkali metal alkylsulphate to reinforce the local availability of active principle and between 0.1% and 1% of a monohydrate sugar.
Owner:VECTANS PHARMA
Methods and compositions based on inhibition of cell invasion and fibrosis by anionic polymers
Owner:TRIAD
Chimeric activators: quantitatively designed protein therapeutics and uses thereof
ActiveUS20110274658A1Reduced cell-activating propertyAvoid and reduce unwanted side effectObesity gene productsPeptide/protein ingredientsChimerin ProteinsApoptosis
Aspects of the invention provide methods for harnessing the potential of proteins that occur naturally (e.g., in humans) and that have serious but finite toxicity. Aspects of the invention relate to a quantitative systems-biological and structural approach to design a class Mof chimeric proteins that avoid the toxicity of protein drugs while retaining their desired activities. In particular, chimeric proteins containing a variant form of a natural protein fused to a targeting moiety may be administered to a subject to target a signal (e.g., induction of apoptosis) to particular cells without having a generalized toxic effect
Owner:PRESIDENT & FELLOWS OF HARVARD COLLEGE
Immunocapture of mitochondrial protein complexes
InactiveUS20050153381A1High-throughput screeningPrevent or treat mitochondrial disordersAnimal cellsCompound screeningDiseasePhosphorylation
Provided herein is a library of monoclonal antibodies specific for native proteins and native protein complexes of the oxidative phosphorylation (OXPHOS) system (for example, Complex I, II, III, IV, or V, or any protein subunit of any of such complexes). Hybridomas expressing such antibodies and antibodies that competitively inhibit the binding of any such antibody (e.g., antibodies that bind the same or a sterically overlapping epitope) are also contemplated. Methods of using, and kits including, the disclosed antibodies are also provided. Antibodies, methods and kits described herein address a need in the art by providing immunological reagents and assays useful, at least, for detecting mitochondrial diseases associated with deficiencies or alterations in OXPHOS Complexes I, II, III, IV and / or V.
Owner:OREGON HEALTH & SCI UNIV +1
Polynucleotides and polypeptides of the erythropoietin gene
InactiveUS20030050269A1Increase productionNervous disorderPeptide/protein ingredientsErythroid cellErythropoietin Gene
The present invention relates to new polynucleotides deriving from the nucleotide sequence of the EPO gene and comprising new SNPs, new polypeptides derived from the natural EPO protein and comprising at least one mutation caused by the SNPs of the invention as well as their therapeutic uses.
Owner:GENODYSSEE SA
Peroxisome biogenesis factor protein (PEX) disruptions for altering polyunsaturated fatty acids and total lipid content in oleaginous eukaryotic organisms
InactiveUS20090117253A1Lipid content in PEX-disrupted can be increased and decreasedFungiNervous disorderBiotechnologyOrganism
Methods of increasing the amount of polyunsaturated fatty acids (PUFAs) in the total lipid fraction and in the oil fraction of PUFA-producing, oleaginous eukaryotes, accomplished by modifying the activity of peroxisome biogenesis factor (Pex) proteins. Disruptions of a chromosomal Pex3 gene, Pex10p gene or Pex16p gene in a PUFA-producing, oleaginous eukaryotic strain resulted in an increased amount of PUFAs, as a percent of total fatty acids and as a percent of dry cell weight, in the total lipid fraction and in the oil fraction of the strain, as compared to the parental strain whose native Pex protein was not disrupted.
Owner:EI DU PONT DE NEMOURS & CO
Enzyme linked immunosorbent assay kit for combined diagnosis of gastrosis or evaluation of gastric cancer risks
InactiveCN102087279AIncreased sensitivityImprove featuresComponent separationTissue cultureAntigenPepsinogen I
The invention discloses an enzyme linked immunosorbent assay kit for combined diagnosis of the gastrosis or evaluation of gastric cancer risks and a preparation method thereof. The kit comprises a micropore plate coated with an antibody against a pepsin antigen I or an antibody against a pepsin antigen II, an enzyme labeled antibody, a color-developing agent, a stop solution and a concentrated cleaning solution, wherein the pepsin antigen I or the pepsin antigen II is a natural protein obtained from extraction of human gastric mucosa tissue. The kit disclosed by the invention adopts a mouse immunized with pepsinogen I and pepsinogen II which are separated from human gastric mucosa to prepare immunogen of a monoclonal antibody, the used standard sample also adopts the pepsin antigen I or the pepsin antigen II separated from the human gastric mucosa, thereby the defects caused by adopting different structures of animal pepsinogen and human pepsinogen are filled. The kit can be used for accurately diagnosing the gastrosis or early gastric cancer and has the advantages of high sensitivity, strong specificity, good accuracy and the like.
Owner:BEIJING MOKOBIO LIFE SCI CO LTD
Growth factor modified protein matrices for tissue engineering
InactiveUS7247609B2Reduce drug doseGreat percentagePeptide/protein ingredientsAntibody mimetics/scaffoldsTissue repairDrug release
Proteins are incorporated into protein or polysaccharide matrices for use in tissue repair, regeneration and / or remodeling and / or drug delivery. The proteins can be incorporated so that they are released by degradation of the matrix, by enzymatic action and / or diffusion. As demonstrated by the examples, one method is to bind heparin to the matrix by either covalent or non-covalent methods, to form a heparin-matrix. The heparin then non-covalently binds heparin-binding growth factors to the protein matrix. Alternatively, a fusion protein can be constructed which contains a crosslinking region such as a factor XIIIa substrate and the native protein sequence. Incorporation of degradable linkages between the matrix and the bioactive factors can be particularly useful when long-term drug delivery is desired, for example in the case of nerve regeneration, where it is desirable to vary the rate of drug release spatially as a function of regeneration, e.g. rapidly near the living tissue interface and more slowly farther into the injury zone. Additional benefits include the lower total drug dose within the delivery system, and spatial regulation of release which permits a greater percentage of the drug to be released at the time of greatest cellular activity.
Owner:ETH ZZURICH +1
Growth factor modified protein matrices for tissue engineering
InactiveUS6894022B1Improve the level ofRaise the ratioOrganic active ingredientsPeptide/protein ingredientsTissue repairProtein incorporation
Proteins are incorporated into protein or polysaccharide matrices for use in tissue repair, regeneration and / or remodeling, and / or drug delivery. The proteins can be incorporated so that they are released by degradation of the matrix, enzymatic action, and / or diffusion. In one embodiment, a fusion protein, which contains a crosslinking region, such as a factor XIIIa substrate, and a native protein sequence, such as a bioactive factor, is constructed. Degradable linkages may be included between the crosslinking region and the bioactive factor.
Owner:UNIV ZURICH +1
Protein synthetic fibre spinning solution and its producing method
InactiveCN1364948ASkin-friendlyBreathableConjugated cellulose/protein artificial filamentsPolymer scienceAmino acid side chain
The protein fiber spinning solution is produced by using animal and plant material and through the processes of acid pickling, extraction, pH regulation to obtain protein curd, dissolving with cosolvent to form water solution, mixing, modifying side chain of amino acid with modifying agent, copolymerization with coloring monomer, mixing with PVA water solution and addition crosslinking agent to regualte viscosity. It may be used in spinning fiber with the same strengt has chemical fiber, the skin friendship, air penetrability and hygroscopicity the same as natural protein fiber, and improved hot water resistance, shrinkage and color.
Owner:卓宝松 +1
Hairpin peptides with a novel structural motif and methods relating thereto
InactiveUS6914123B2Enable stabilizationImprove structural stabilityPeptide/protein ingredientsLibrary screeningProtein moleculesModel system
The invention is directed to a model system for structure-activity relationship analysis of peptide or protein molecules involved in important biological processes. Provided by the invention are combinatorial peptide libraries comprising peptides with a novel “tryptophan zipper” scaffold (trpzip) that forms stable β-hairpin structure in solution. Methods of selecting and using such scaffold are provided herein, which are useful for mimicking native protein structures and interactions and designing therapeutic agents. Thus, the invention has profound utility for biological studies and drug development.
Owner:GENENTECH INC
Multivalent Heteromultimer Scaffold Design and Constructs
ActiveUS20140066378A1Function increaseImprove stabilityBacteriaPeptide/protein ingredientsNative structureMolecular entity
Provided herein are multifunctional heteromultimer proteins. In specific embodiments is a heteromultimer comprising: at least two polypeptide constructs, each polypeptide construct comprising at least one cargo polypeptide attached to a transporter polypeptide, said transporter polypeptides derived from a monomeric native protein such that said monomeric constructs associate to form the heteromultimer and said transporter polypeptides associate to form a quasi-native structure of the monomeric native protein or analog thereof. These therapeutically novel molecules encompass heteromultimers comprising constructs that function as scaffolds for the conjugation or fusion of therapeutic molecular entities (cargo polypeptides) resulting in the creation of bispecific or multivalent molecular species. Provided herein is a method for creation of bispecific or multivalent molecular species.
Owner:ZYMEWORKS INC
Preparation method of recombinant spider silk protein/silver nano biological wound membrane
InactiveCN103041440AImprove antibacterial propertiesSimple preparation processAbsorbent padsBandagesArginineProtein materials
The invention relates to a preparation method of a recombinant spider silk protein / silver-bearing nano wound membrane. The preparation method comprises the steps of dissolving PVA (Polyvinyl Acetate) in H2O to prepare a PVA aqueous solution, conducting electrostatic spinning to prepare PVA nanofiber membrane, uniformly spraying a silver nitrate weak solution onto the PVA nanofiber membrane, drying, dissolving pNSR 16 in formic acid to prepare a formic acid solution of RGD (Arginine-Glycine-Aspartate)-spider silk protein, electrically spinning the formic acid solution of the RGD-spider silk protein into the PVA nanofiber membrane by an electrostatic spinning technology to form a pNSR 16 composite silver-bearing PVA nanofiber membrane, dyring, and obtaining the silver-bearing nano biological wound membrane. The membrane adopts natural protein materials and has bioactivity; as silver nitrate antibacterial components are introduced, the membrane has a significant antibacterial property and can kill most gram-negative bacteria and gram-positive bacteria; with the adoption of the electrostatic spinning technology, the preparation process is simple; and compared with medical gauze, the number of days required by complete healing of animal skin is reduced by approximately one third.
Owner:FUJIAN NORMAL UNIV
Stable isotope labeled polypeptide standards for protein quantitation
InactiveUS20060154318A1Increase heightDepsipeptidesPeptide preparation methodsStable Isotope LabelingProtein target
This invention relates to proteins having an amino acid sequence containing several amino acid subsequences found in nature and wherein at least two different subsequences act as monitor sequences, said subsequences being part of at least one natural protein which is a target protein, wherein the end of each of said two different subsequences have a cleavage site that will be cleaved by the same site-specific proteolytic treatment to release said subsequences.
Owner:ANDERSON FORSCHUNG GROUP
Method for preparing biological filler for injectable soft tissue
A process for preparing the biologic filler able to be injected in soft tissue for repairing it or beautifying skin includes such steps as providing the fresh skin of piglet, removing subcutaneous fat, immersing in defatting liquid for defatting, defatting again, alkali treating, removing alkali, cutting for layering, softening by enzyme liquid, cross-linking, water washing, bleaching, cutting to become particles, packing and Co-60 irradiation.
Owner:SHANDONG UNIV
T1R3 transgenic animals, cells and related methods
InactiveUS20050177886A1Animal cellsPeptide/protein ingredientsTaste transductionGenetically modified animal
The present invention relates to the discovery, identification and characterization of a receptor protein, referred to herein as T1R3, which is expressed in taste receptor cells and associated with the perception of bitter and sweet taste. The invention encompasses transgenic animals and cells that do not express functional T1R3 protein, particularly knock-out animals and cells, and transgenic animals and cells that express a non-native T1R3 protein. Experimental model systems based on these animals and cells can be used to study T1R3-mediated taste transduction and responses of the components of the T1R3 signal transduction pathway to various tastants, furthering our understanding of the molecular biology and biochemistry of taste. Such model systems would also be useful for screening for novel tastants and taste modulators, such as enhancers of desirable flavors, and blockers of undesirable flavors.
Owner:MT SINAI SCHOOL OF MEDICINE
Mitochondrial targeting and therapeutic use thereof
ActiveUS20140135275A1Enhance cell viabilityCompounds screening/testingBacteriaFrataxinMitochondrion membrane
The present invention provides, among other things, compositions and methods for treatment of Friedrich's Ataxia based on effective targeting of a therapeutic moiety to mitochondria that can substitute for natural FXN protein activity or rescue one or more phenotypes or symptoms associated with frataxin-deficiency. In some embodiments, the present invention provides a targeted therapeutic comprising a therapeutic moiety, which is a polypeptide having an N-terminus and a C-terminus, a mitochondrial targeting sequence associated with the therapeutic moiety at the N-terminus, and a mitochondrial membrane-penetrating peptide associated with the therapeutic moiety at the C-terminus, wherein the therapeutic moiety is targeted to mitochondria upon cellular entry.
Owner:TAKEDA PHARMA CO LTD
Modified gum arabic
ActiveUS20050124805A1Low protein nitrogen contentDifferent molecular weightCosmetic preparationsTransportation and packagingNatural variationGum arabic
The present invention provides a water-soluble modified gum arabic with a weight average molecular weight not less than 0.9 million and arabinogalactan protein not less than 17% by weight obtained by heating Acacia Senegal gum arabic and modified water-soluble gum arabic with a weight average molecular weight not less than 2.5 million and with protein containing high molecular weight components of not less than 25% by weight. Moreover, the present invention provides modified gum arabic with standardized and predictable molecular properties and methods for providing the modified gum arabic endowed with high emulsification efficiency and stability and for uniforming natural variations in unmodified gum arabic. The present invention changes the natural protein distribution of gum arabic, and increases AGP content.
Owner:SAN EI GEN F F I
SUMO Fusion Protein Expression System for Producing Native Proteins
ActiveUS20090280535A1Peptide/protein ingredientsImmunoglobulinsFusion Protein ExpressionProtein formation
Owner:ACAD SINIC
Cosmetic and/or dermopharmaceutical preparations containing native proteins from the plant argania spinosa
InactiveUS20040042996A1Rapid and sensitive for quantitationMaintain good propertiesBiocideCosmetic preparationsBiologyNative protein
A cosmetic and / or dermopharmaceutical composition containing an extract of native proteins derived from the plant Argania spinosa.
Owner:COGNIS FRANCE SA
Bio-friendly antibacterial coating capable of effectively fixing cationic antibacterial agent and resisting bacterial biofilm
ActiveCN111773439AOvercome drug resistanceAvoid stickingSurgeryPharmaceutical delivery mechanismLactalbuminAntibacterial agent
The invention discloses a bio-friendly antibacterial coating capable of effectively fixing a cationic antibacterial agent and resisting a bacterial biofilm. The coating can be formed on the surface ofa to-be-modified substrate by placing the to-be-modified substrate in impregnation liquid, and the impregnation liquid is formed by mixing protein, the cationic antibacterial agent and a reducing agent; negative charges, which are presented in an environment with an isoelectric point larger than that of natural proteins such as serum albumin, fibrinogen, alpha-lactalbumin and the like by the natural proteins, can be mutually neutralized with positive charges of the cationic antibacterial agent, thereby obtaining the coating with a surface close to electric neutrality, protein and bacterial debris adsorption can be effectively avoided, the long-term efficient antibacterial and anti-biofilm effects are maintained, and meanwhile, the defect of poor biocompatibility of the bactericidal surface of a traditional cationic antibacterial agent is overcome. The coating disclosed by the invention is simple and convenient in preparation method, biologically safe and universally applicable to thesurfaces of various medical devices, the bactericidal effect of the coating is achieved without depending on antibiotics, and bacterial drug resistance caused by improper use of antibiotics can be effectively avoided.
Owner:SHAANXI NORMAL UNIV
Analog of Haemophilus Hin47 with reduced protease activity
An isolated and purified analog of Haemophilus influenzae Hin47 protein has a decreased protease activity which is less than about 10% of that of natural Hin47 protein and preferably substantially the same immunogenic properties as natural Hin47 protein. An isolated an purified nucleic acid molecule encoding the Hin47 analog may be provided in a recombinant plasmid which may be introduced into a cell which is grown to produce the Hin47 analog. Immunogenic compositions comprising the Hin47 analog and the encoding nucleic acid may be formulated as vaccines for in vivo administration to a host, including a human, to confer protection against diseases caused by a bacterial pathogen, including Haemophilus species, such as Haemophilus influenzae, that produces Hin47 protein or a protein capable of inducing antibodies in the host specifically reactive with Hin47 protein. The Hin47 analog and the encoding nucleic acid also may be employed in diagnostic applications.
Owner:CONNAUGHT LAB
Hepatitis B virus surface L protein related peptide
The invention relates to peptides derived from HBV L protein for the prevention and treatment of Hepatitis B virus (HBV) infection, screening method for removing antigenicity of these peptides and the deantigenic derivative peptide screened through the method, wherein the HBV surface L protein pre-S1 region contains key amino acid sequence of the virus adhesion cell surface acceptor and antigenic amino acid sequence bonding with the anti-L protein antibody. The polypeptides at the HBV surface L protein pre-S1 region can suppress HBV infection to cells. The invention also provides the screening method for removing the antigenicity of these polypeptides.
Owner:SHANGHAI HEP PHARMA
Cosmetic and/or dermopharmaceutical preparations containing native proteins from the plant Argania spinosa
InactiveUS7871766B2Maintain good propertiesGood effectCosmetic preparationsBiocideBiologyNative protein
Owner:COGNIS FRANCE SA
Method for producing a soy milk
InactiveUS20090317533A1High protein yieldIncrease productionMilk treatmentProtein composition from vegetable seedsSlurrySoya bean
A method of production of a soymilk or a soy-based beverage. The method includes the following processing steps: providing soybeans for processing; soaking the soybeans; grinding the soybeans to form a slurry; separating the soy slurry into soymilk and okara in a centrifugal field. The soaking and grinding are carried out at temperatures from 0° C. to 40° C., which temperatures yield native proteins. Further included is a step of deodorizing the soymilk to reduce the beany taste.
Owner:WESTFALIA SEPARATOR AG
Use of hydrostatic pressure to inhibit and reverse protein aggregation and facilitate protein refolding
InactiveUS20050020818A1High protein concentrationSuitable for useDepsipeptidesPeptide preparation methodsInclusion bodiesCell Aggregations
A novel approach is described for reversing aggregation and increasing refolding by application of hydrostatic pressure. A protein of interest in an aggregated, or inclusion body, or other non-native or inactive state is subjected to high hydrostatic pressure. This treatment denatures the protein to states (or conformations) competant for refolding and results in increased formation of native protein once pressure is released. The technique can facilitate conversion non-native proteins, including inclusion bodies and aggregates to native proteins without addition of chaotropic agents, changes in buffer, or large-scale dilution of reagents required for traditional refolding methods.
Owner:BARFOLD INC +1
Novel duck reovirus recombinant sigma B protein antigen, preparation method and application
InactiveCN102675469ANo cross reactionHigh detection sensitivityPeptide preparation methodsFermentationInclusion bodiesNucleotide
The invention discloses preparation of novel duck reovirus recombinant sigma B protein antigen, and application of the novel duck reovirus recombinant sigma B protein antigen in detection of a novel duck reovirus antibody. With RNA (ribonucleic acid) of the novel duck reovirus (NDRV) as a template, a nucleotide complete sequence of an NDRV S3 gene coding region can be amplified through a reverse-translation polymerase-chain reaction, is directionally subcloned to a fusion expression vector of the prokaryotic expression vector pET-30a-C(+) of escherichia coli, and transformed into the host cell of the Escherichia coli BL21 (DE3), and is subjected to inducible expression with IPTG (isopropyl-beta-d-thiogalactoside), purification of Ni-NTA Agarose, inclusion body refolding to obtain the expressed NDRV alpha B recombinant protein antigen. The expression mode of the protein is fusion protein (His-alpha B) with molecular weight being about 44kU; and immunoblotting assays prove that the protein has immunoreactivity similar to natural protein..
Owner:INST OF ANIMAL HUSBANDRY & VETERINARY FUJIAN ACADEMY OF AGRI SCI
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com